MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.34. Operator: Hello. Thank you for standing by ...

Insiders are still scooping up shares of stocks, including huge buys at two energy companies, an apparel retailer, and a ...